P95 and Julius Clinical Merge to Enhance Clinical Research
P95 and Julius Clinical have announced a major merger, creating a formidable global clinical research organization (CRO). This new entity will harness the power of combined expertise across various fields such as neuroscience, cardio-renal-metabolic disorders, and infectious diseases, including vaccines. Together, they boast a workforce of over 500 professionals located in more than 25 countries, dedicated to clinical development and real-world evidence programs worldwide.
Strengths and Capabilities of the Merged Organization
The merger combines the unique strengths of both organizations, delivering a blended service of clinical trial capabilities and integrated epidemiological research. With Julius Clinical's seasoned clinical trial proficiency and P95's robust background in epidemics and vaccine research, the two firms will now offer a holistic platform. This platform is designed to better serve biopharmaceutical and public health partners throughout the entire development lifecycle.
Leadership and Vision for the Future
Under the leadership of Dr. Bassem Saleh, the current CEO of Julius Clinical, the company aims to propel itself into new realms of clinical excellence. Meanwhile, Dr. Thomas Verstraeten, founder and former CEO of P95, will continue his involvement as a board member and senior advisor, ensuring the organization maintains a steady course in scientific leadership and strategy.
Commitment to Global Health Improvement
Dr. Saleh expressed enthusiasm for the merger, underscoring the shared mission of both organizations: to enhance global health through scientific integrity and quality research. This commitment empowers teams and clients alike, as they embark on innovative projects that strive to improve lives across the globe.
Support from Ampersand Capital Partners
The merger enjoys the backing of Ampersand Capital Partners, a reputable investor in both entities. Ampersand's involvement signals a commitment to supporting the newly formed organization as it expands its global presence while reinforcing its operational capacities and growth initiatives.
Global Reach with Local Expertise
With a diverse workforce set across North America, Europe, Africa, Latin America, and Asia-Pacific, the newly merged company can offer a wide-reaching service base with localized expertise. Their comprehensive skill set encompasses aspects of clinical operations, data analytics, biostatistics, and medical leadership. Clients, including both large pharmaceutical firms and innovative biotech companies, stand to gain significantly from the increased capabilities and strategic integration of clinical and real-world evidence.
About P95
P95 establishes itself as a prominent figure in the global clinical solutions landscape, specializing in epidemiology and vaccine research. With headquarters in Belgium and regional offices spread across Africa, North America, and Southeast Asia, P95's services are stretched across five continents. Their offerings include extensive clinical trials, epidemiology studies, and an array of consulting services that address client needs.
About Julius Clinical
Julius Clinical, founded in 2008, is highly regarded for its focus on central nervous system disorders and other significant healthcare challenges. With a plethora of clinical trials conducted and a broad portfolio of services, Julius Clinical is adept at tailoring solutions for biotech and mid-sized pharmaceutical companies, reinforcing its reputation as a leader in the clinical research domain.
Frequently Asked Questions
What prompted the merger between P95 and Julius Clinical?
The merger was driven by the desire to combine strengths in clinical research and epidemiology, enhancing the capacity for concurrent global health initiatives.
Who will lead the newly formed organization?
Dr. Bassem Saleh, the CEO of Julius Clinical, will take charge as the Chief Executive Officer of the merged organization.
How will the merger affect clients?
Clients will benefit from an expanded range of services and expertise, resulting in enhanced solutions for clinical development and public health needs.
Where are the offices located?
The merged company has a global presence, with operational offices in North America, Europe, Africa, Latin America, and Asia-Pacific.
What areas of research do P95 and Julius Clinical specialize in?
They specialize in various fields, including neuroscience, infectious diseases, cardio-renal-metabolic disorders, and vaccine research, providing comprehensive services across these domains.
